At a glance
ClinicalIndex Comparison Record- ✓Age 18-54 years old
- ✓ADHD NOS diagnosis by DSM-IV, confirmed by structured interview: either ≥6/9 current inattention or hyperactivity/impulsivity items with <5 childhood items, OR 5/9 current items without 6 in either category
- ✓Clinical Global Impression ADHD score ≥4
- ✓Can have past depression/anxiety disorder if none currently for >3 months
- ✕Unstable psychiatric conditions: acute psychosis, acute panic, acute OCD, acute mania, acute suicidality, lifetime bipolar disorder, acute substance use, sociopathy, criminality
- ✕Metabolic, neurological, hepatic, renal, cardiovascular, hematological, ophthalmic, or endocrine disease
- ✕Mental retardation (IQ <75)
- ✕Organic brain disorders
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified
In Brief
A Phase 4 clinical trial evaluating Strattera (atomoxetine) for ADHD NOS. Completed, enrolled 45 participants across 1 site.
Detailed Summary
This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the treatment of adults with attention deficit hyperactivity disorder not otherwise specified. The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day, whichever is less) in adults with ADHD NOS will be safe and well tolerated.
Study Details
Timeline
Interventions
Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).